Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This study designed to determine the Maximum Tolerated Dose (MTD) for patients with advanced
Neuroendocrine Tumors (NETs) and to characterize the safety, tolerability, Pharmacokinetics
and preliminary efficacy of pasireotide LAR administered i.m. once every 28 days.